The US Food and Drug Administration ’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended approval of Novartis’ CTL019 (tisagenlecleucel) for the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (…

Related Links:

ConclusionOMF ALL/LBL is rare, but its microscopic features and immunohistochemical profiles CD3+or CD79 a+/CD10+/CD34+variable/CD99+/TdT+ contribute to the correct diagnosis.

Publication date: October 2018Source: Biocatalysis and Agricultural Biotechnology, Volume 16Author(s): Marília Crivelari da Cunha, Laura Carvalho Silva, Hélia Harumi Sato, Ruann Janser Soares de CastroAbstractMicrobial L-asparaginase have been used as a therapeutic agent in the treatment of acute lymphoblastic leukemia and Hodgkin’s disease. In addition to clinical use, L-asparaginases have been used in foods to reduce the formation of acrylamide. L- asparaginase production is carried out mainly by submerged fermentation (SmF). However, solid-state fermentation (SSF) offers potential benefits compared with su…

Measurable residual disease (MRD) is arguably the most useful single prognostic tool we have within the field of acute lymphoblastic leukemia (ALL), discusses Anthony Moorman, PhD, of Newcastle Univer…


Author: VJHemOnc
Added: 07/18/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research. Here, Oliver Ottmann, MD, FRCPath, of Cardiff Univer…


Author: VJHemOnc
Added: 07/18/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

There are promising results from a variety of studies implicating CAR T-cells in relapsed/refractory acute lymphoblastic leukemia (ALL) treatment. Here, William Wierda, MD, PhD, of the MD Anderson Can…


Author: VJHemOnc
Added: 07/18/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Inotuzumab ozogamicin has shown extremely promising results in clinical trials for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). There are, however, still issues with legislatio…


Author: VJHemOnc
Added: 07/18/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

We should move away from using risk factors as individual binary variables within acute lymphoblastic leukemia (ALL) research, suggests Anthony Moorman, PhD, of Newcastle University, Newcastle, UK, at…


Author: VJHemOnc
Added: 07/18/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

The Phase III INO-VATE trial (NCT01564784) showed improved rates of complete remission and overall survival in relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin…


Author: VJHemOnc
Added: 07/18/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Anthony Moorman, PhD, of Newcastle University, Newcastle, UK, discusses the current UKALL14 trial (NCT01085617) for adults aged 25-65 with acute lymphoblastic leukemia (ALL). The trial is the first of…


Author: VJHemOnc
Added: 07/18/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Publication date: Available online 17 July 2018Source: The Lancet HaematologyAuthor(s): Mark P Little, Richard Wakeford, David Borrego, Benjamin French, Lydia B Zablotska, M Jacob Adams, Rodrigue Allodji, Florent de Vathaire, Choonsik Lee, Alina V Brenner, Jeremy S Miller, David Campbell, Mark S Pearce, Michele M Doody, Erik Holmberg, Marie Lundell, Siegal Sadetzki, Martha S Linet, Amy Berrington de GonzálezSummaryBackgroundSubstantial evidence links exposure to moderate or high doses of ionising radiation, particularly in childhood, with increased risk of leukaemia. The association of leukaemia with exposure to low-dose (





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image